Zentalis Pharmaceuticals, Inc.

NasdaqGM:ZNTL Stock Report

Market Cap: US$963.6m

Zentalis Pharmaceuticals Dividend

Dividend criteria checks 0/6

Zentalis Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$4.12
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Feb 29
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Feb 05

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Jan 09
Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Oct 13
We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Jun 30
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Dec 01
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Sep 27

Zentalis Pharmaceuticals has a new chief medical officer

Sep 19

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Aug 17
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

May 02
Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Oct 14
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jul 02
Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Mar 08
Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jan 20
Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Zentalis initiates multiple early-stage clinical trials for cancer

Jan 06

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Nov 28
Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Zentalis: An Interesting Small Molecule Oncology Developer For Your Watchlist

Nov 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ZNTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZNTL's dividend payments have been increasing.


Dividend Yield vs Market

Zentalis Pharmaceuticals Dividend Yield vs Market
How does ZNTL dividend yield compare to the market?
SegmentDividend Yield
Company (ZNTL)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (ZNTL)0%

Notable Dividend: Unable to evaluate ZNTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZNTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ZNTL's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ZNTL has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.